Pfizer Inc. $PFE Shares Purchased by Capital Advisors Inc. OK

Capital Advisors Inc. OK grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,640,726 shares of the biopharmaceutical company’s stock after purchasing an additional 105,365 shares during the quarter. Capital Advisors Inc. OK’s holdings in Pfizer were worth $40,854,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer during the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the 2nd quarter valued at about $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $32,000. Finally, True Wealth Design LLC lifted its stake in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PFE shares. Royal Bank Of Canada started coverage on Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price target for the company. Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Citigroup assumed coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Stock Up 1.1%

Shares of PFE opened at $28.08 on Wednesday. The company’s 50-day moving average price is $26.94 and its 200 day moving average price is $25.75. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.31. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a market cap of $159.67 billion, a P/E ratio of 20.65 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the firm posted $0.63 earnings per share. Pfizer’s revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.